CRBP Corbus Pharmaceuticals Holdings Inc.

4.41
-0.17  -4%
Previous Close 4.58
Open 4.56
Price To Book 6.04
Market Cap 285,207,458
Shares 64,672,893
Volume 1,036,420
Short Ratio
Av. Daily Volume 558,967
Stock charts supplied by TradingView

NewsSee all news

  1. Corbus Pharmaceuticals Updates Data from Lenabasum Open-Label Extension Studies in Systemic Sclerosis and Dermatomyositis at 2019 ACR Annual Meeting

    Median ACR CRISS score remains 0.95 at 25 months in systemic sclerosis OLE Improvement in CDASI activity score reaches -20.9 points at 23 months in dermatomyositis OLE Favorable safety profile continues with no serious

  2. Corbus Pharmaceuticals Reports 2019 Third Quarter Financial Results and Provides Clinical and Corporate Updates

    Phase 3 "RESOLVE-1" study of lenabasum for treatment of systemic sclerosis on track for topline results in summer of 2020Systemic sclerosis is a rare autoimmune disease affecting ~200,000 people in the U.S., EU and Japan

  3. Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2019 Operational and Financial Results on November 7, 2019

    - Company to host conference call and webcast on Thursday, November 7 at 8:30 a.m. ET -                Norwood, MA, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or

  4. Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2019 ACR Annual Meeting

    New lenabasum open-label extension study interim data in systemic sclerosis and dermatomyositis to be presentedSystemic sclerosis is a rare autoimmune disease affecting ~200,000 people in the U.S., EU and Japan and has

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b data due summer of 2020.
Anabasum (Resunab)
Cystic Fibrosis
Phase 2 data due 2020.
Anabasum (Resunab)
Systemic lupus erythematosus (SLE)
Phase 3 data due 2021.
Lenabasum (resunab) - DETERMINE
Dermatomyositis
Phase 3 top-line data due summer 2020.
Resunab - RESOLVE-1
Systemic Sclerosis
Phase 1 trial to be initiated in 2020.
CRB-4001
Nonalcoholic steatohepatitis (NASH)

Latest News

  1. Corbus Pharmaceuticals Updates Data from Lenabasum Open-Label Extension Studies in Systemic Sclerosis and Dermatomyositis at 2019 ACR Annual Meeting

    Median ACR CRISS score remains 0.95 at 25 months in systemic sclerosis OLE Improvement in CDASI activity score reaches -20.9 points at 23 months in dermatomyositis OLE Favorable safety profile continues with no serious

  2. Corbus Pharmaceuticals Reports 2019 Third Quarter Financial Results and Provides Clinical and Corporate Updates

    Phase 3 "RESOLVE-1" study of lenabasum for treatment of systemic sclerosis on track for topline results in summer of 2020Systemic sclerosis is a rare autoimmune disease affecting ~200,000 people in the U.S., EU and Japan

  3. Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2019 Operational and Financial Results on November 7, 2019

    - Company to host conference call and webcast on Thursday, November 7 at 8:30 a.m. ET -                Norwood, MA, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or

  4. Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2019 ACR Annual Meeting

    New lenabasum open-label extension study interim data in systemic sclerosis and dermatomyositis to be presentedSystemic sclerosis is a rare autoimmune disease affecting ~200,000 people in the U.S., EU and Japan and has